Solve GNE and Vecgen Awarded NIH Fast-Track STTR Grant to Develop a Diagnostic Predicting Immune Response to AAV Gene Therapy for GNE Myopathy

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has funded a joint Solve GNE–Vecgen project to validate a test that predicts, before treatment, how a patient's immune system will respond to an AAV gene-therapy vector — a key step toward safer patient selection for a GNE myopathy gene therapy, with potential reach across other AAV-based programs.

• $333,689 Phase 1 funded & underway
• ~$2M Phase 2 anticipated from Sept 2027
• NIAMS Awarding NIH institute

Only Phase 1 funding has been obligated by the NIH. Phase 2 amounts are anticipated, not committed, and depend on NIH milestone review and availability of funds. Research reported here is supported by NIAMS of the National Institutes of Health under Award Number R42AR087918; content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.